Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 151.77B |
| Revenue (ttm) | 30.66B |
| Net Income (ttm) | 5.97B |
| Shares Out | n/a |
| EPS (ttm) | 11.02 |
| PE Ratio | 25.42 |
| Forward PE | 15.88 |
| Dividend | 8.52 (3.02%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 152 |
| Average Volume | 497 |
| Open | 278.10 |
| Previous Close | 281.75 |
| Day's Range | 277.25 - 282.05 |
| 52-Week Range | 230.00 - 308.50 |
| Beta | 0.45 |
| RSI | 52.85 |
| Earnings Date | Feb 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Amgen (AMGN) Moves to Reduce Drug Prices in Collaboration with U.S. Government
Amgen (AMGN) Moves to Reduce Drug Prices in Collaboration with U.S. Government
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
9 more drugmakers agree to Trump's policy to lower some prices
The White House announced Friday that nine additional pharmaceutical companies have agreed to follow President Trump's Most Favored Nation (MFN) drug pricing policy, with several of the companies thro...
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif. , Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action aga...
Trump to announce new drug-pricing deals later today
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Takeda's Once-Daily Psoriasis Pill Hits Phase 3 Goals, Beats Amgen's Drug
Takeda Pharmaceutical Co., Ltd (NYSE: TAK) on Thursday announced positive topline results for the two pivotal Phase 3 studies of zasocitinib (TAK-279) for moderate-to- severe plaque psoriasis (PsO) ....
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Amgen (AMGN) Among Pharma Giants in Drug Pricing Talks
Amgen (AMGN) Among Pharma Giants in Drug Pricing Talks
This biotech name is evolving into a major obesity play. How to trade it with options
Key catalysts, including growing confidence around Amgen’s MariTide obesity program, could transform the name into a growth story.
Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026?
The Dow Jones tracks 30 of the largest American companies across different sectors. Verizon, Chevron, and Merck hold the highest dividend yields in the Dow Jones.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Amgen (AMGN) settling at $325.31, representing a +2.38% change from its previous close.
Dow Analyst Moves: AMGN
The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Amgen is the #15 analyst pick. Within the broader S&P 50...
XLV, AMGN, GILD, MDT: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we...
2 Dividend Stocks to Double Up on Right Now
These two pharmaceutical giants have faced -- or will soon face -- patent cliffs. Both are innovative drugmakers, which should allow them to overcome this issue.
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leukemia Treatment
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leukemia Treatment
FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA® (inebilizumab-cdon) for the tre...
Amgen (AMGN) Receives Maintained Rating, Price Target Lowered to $304 by Morgan Stanley | AMGN ...
Amgen (AMGN) Receives Maintained Rating, Price Target Lowered to $304 by Morgan Stanley | AMGN Stock News
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasthenia Gravis
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasthenia Gravis
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
Amgen (AMGN) Gains FDA Approval for New Treatment Uplinza
Amgen (AMGN) Gains FDA Approval for New Treatment Uplinza
FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis
(RTTNews) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive for anti-acetylcholine r...